Security Snapshot

NextCure, Inc. - Common Stock, par value $0.001 per share (NXTC) Institutional Ownership

CUSIP: 65343E108

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.45

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
NXTC on Nasdaq
Shares outstanding
3,602,511
Price per share
$0.45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • NXTC - NextCure, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 65343E108.
  • Latest finished 13F holder period is not available.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $127,941 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Security key

65343E108

Latest holder period

n/a

13F holders

13D/G owners

3

CIK / CUSIP context first

NXTC full holder history NextCure, Inc. SEC filings NextCure, Inc. company facts NextCure, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of NextCure, Inc. - Common Stock, par value $0.001 per share (NXTC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CITIGROUP INC 4.3% $506,181 1,205,193 Citigroup Global Markets Inc. 31 Mar 2025
Simcere Zaiming, Inc. 9.4% $152,386 338,636 Simcere Zaiming, Inc. 31 Dec 2025
PFIZER INC 3% $923,806 157,646 Pfizer Inc. (IRS Identification No.: 13-5315170) 31 Dec 2025

Institutional Holders of NextCure, Inc. - Common Stock, par value $0.001 per share (NXTC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$127,941 $0.45 0
2025 Q3 21,833 $127,941 -$6,933,824 $5.86 1
2025 Q2 10,545,575 $5,647,089 -$11,042,788 $0.46 29
2025 Q1 15,365,612 $7,377,835 -$659,368 $0.48 38
2024 Q4 14,576,884 $11,238,169 -$3,082,628 $0.77 45
2024 Q3 15,865,008 $21,732,882 -$163,706 $1.37 44
2024 Q2 16,009,076 $25,452,390 -$417,831 $1.59 47
2024 Q1 16,144,047 $35,999,098 +$6,299,292 $2.23 46
2023 Q4 13,341,936 $15,275,154 -$369,923 $1.14 42
2023 Q3 12,895,574 $16,633,500 -$700,863 $1.29 39
2023 Q2 13,318,875 $23,971,765 +$169,807 $1.80 42
2023 Q1 13,265,273 $19,631,094 -$159,489 $1.48 42
2022 Q4 13,389,531 $18,876,133 -$5,000,007 $1.41 44
2022 Q3 15,242,782 $41,759,784 +$1,686,368 $2.75 48
2022 Q2 14,456,827 $67,938,572 +$5,637,581 $4.70 49
2022 Q1 13,233,257 $64,321,105 -$6,638,844 $4.86 57
2021 Q4 14,366,664 $86,200,310 -$4,439,158 $6.00 68
2021 Q3 14,744,107 $99,459,595 -$5,380,167 $6.74 66
2021 Q2 15,461,583 $124,156,911 -$24,114,984 $8.03 74
2021 Q1 17,959,308 $179,779,328 +$33,903,656 $10.01 91
2020 Q4 14,545,518 $158,547,717 -$35,131,387 $10.90 80
2020 Q3 18,265,185 $160,694,375 -$76,990,689 $8.80 73
2020 Q2 20,244,521 $434,046,210 -$4,189,870 $21.44 87
2020 Q1 20,204,298 $748,968,161 -$2,574,956 $37.07 81
2019 Q4 20,192,753 $1,137,417,349 +$381,121,391 $56.33 88
2019 Q3 11,288,924 $348,260,350 +$50,213,398 $30.85 52
2019 Q2 10,754,678 $161,093,210 +$161,093,000 $14.98 42
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .